4D分子治疗学和Otsuka正在开发一种眼病基因疗法,Otsuka在APAC市场领先。 4D Molecular Therapeutics and Otsuka are developing a gene therapy for eye diseases, with Otsuka leading in APAC markets.

4D分子治疗学与Otsuka制药公司合作,在整个亚太区域开发并商业化了4D-150,这是一种用于湿性AMD和糖尿病眼肿的基因疗法。 4D Molecular Therapeutics has partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a gene therapy for wet AMD and diabetic macular edema, across the Asia-Pacific region. Otsuka将领导日本、中国、澳大利亚和其他亚太技援中心国家的监管和商业工作,而4DMT继续全球第三阶段试验,到2025年底开放亚太技援中心场址,到2026年1月开放日本场址。 Otsuka will lead regulatory and commercial efforts in Japan, China, Australia, and other APAC countries, while 4DMT continues global Phase 3 trials, with APAC sites opening by late 2025 and Japan sites by January 2026. 4DMT公司收到一笔8 500万美元的预付付款,最高达3.36亿美元里程碑付款,以及分级的两位数版版权使用费,保留对APAC以外市场的权利。 4DMT received an $85 million upfront payment, up to $336 million in milestone payments, and tiered double-digit royalties, retaining rights to markets outside APAC. 该疗法使用AAVV矢量,以一次性注射方式提供长期抗VEGF治疗。 The therapy uses an AAV vector to deliver long-term anti-VEGF treatment with a single injection.